Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPX0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $76,868
Award facts
- Contract value 100% obligated
- $76,867.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $76,867.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The delivery order, issued on December 10, 2025, with an ultimate completion date of January 2, 2026, carries no set-aside designation, indicating the award was made through full and open competition. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
EXPAREL is a specialty surgical anesthetic product used for infiltration and nerve block procedures in military and civilian medical settings. DMS Pharmaceutical Group's award reflects the company's established capability to supply high-value specialty pharmaceuticals and its demonstrated performance across the Defense Logistics Agency's medical supply chain. The vendor maintains a comprehensive product portfolio spanning oncology treatments, immunosuppressants, biologics, vaccines, and specialty surgical products, positioning it as a critical supplier within the federal pharmaceutical supply chain supporting DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQPX0?
SPE2DR26FQPX0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FQPX0 worth?
The government has obligated $76,868 on SPE2DR26FQPX0.
Is contract SPE2DR26FQPX0 an order under another contract?
Yes. SPE2DR26FQPX0 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPX0 competed?
The extent of competition for SPE2DR26FQPX0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award